Introducing the Third Generation of ISCOM1 Technology
Isconova's adjuvant technology platform meet the need in modern vaccine development and antibody production of an industrially proven high performance novel adjuvant. The outstanding safety profile and exceptional efficacy are the key characteristics of the third generation ISCOM technology that Isconova now is proud to introduce.
1) ISCOM is a registered trademark of CSL Limited, Australia. For more information See Trademarks.
Benefits of AbISCO® adjuvants
- Very well proven with low risk
- High quality immune response
- Highly efficient plus lower doses
- Non-toxic and free from side-effects
- Broad, general use
- Simple-to-use
Isconova secures 30 million Swedish kronor growth financing
(08-06-27) Leading vaccine adjuvant provider set to grow in animal vaccine market and to unlock the value of its technology for human vaccines.
Isconova announces New board of Directors (in Swedish only)
(07-09-26) Isconova har utsett Lars Gårdö, tidigare bla VD För investmentbolaget Atle och ordförande i 3i Nordic, till ny ordförande. Styrelsen förstärks samtidigt med flera företrädare för bioteknik- och läkemedelsindustrin.
For information in English, please see Board of Directors